secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2026-06-03T20:43:17+00:00
Accession:  0001628280-26-040447
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Acumen stockholders elect three Class II directors, approve equity plan
-----------------------------------------------------------------------

- Elected Golumbeski (37.3M for), Porter (30.9M for), Stoppel (30.8M for) as Class II directors.
- Ratified Ernst & Young as auditor for FY 2026: 56.9M for, 113k against.
- Approved Amended and Restated 2021 Equity Incentive Plan: 30.7M for, 6.6M against, 19.7M broker non-votes.
- Turnout: 57.1M of 72.2M shares (78.99%) present or represented at annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/abos-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-040447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer